Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug;9(4):599-602.
doi: 10.1093/ckj/sfw030. Epub 2016 May 4.

Pure red cell aplasia induced by epoetin zeta

Vincenzo Panichi  1 , Guido Ricchiuti  1 , Alessia Scatena  1 , Lucia Del Vecchio  2 , Francesco Locatelli  2
Affiliations

Pure red cell aplasia induced by epoetin zeta

Vincenzo Panichi et al. Clin Kidney J. 2016 Aug.

Abstract

Pure red cell aplasia (PRCA) may develop in patients with chronic kidney disease receiving erythropoiesis-stimulating agents (ESA). We report on a 72-year-old patient who developed hypo-proliferative anaemia unresponsive to ESA following the administration of epoetin zeta subcutaneously for 7 months. On the basis of severe isolated hypoplasia of the erythroid line in the bone marrow and high-titre neutralizing anti-erythropoietin antibodies (Ab), a diagnosis of Ab-mediated PRCA was made. Epoetin zeta was discontinued and the patient was given steroids. This was associated with anaemia recovery. To our knowledge this is the first PRCA case related to epoetin zeta.

Keywords: anaemia; chronic kidney disease; epoetin zeta; erythropoietin; pure red cell aplasia.

PubMed Disclaimer

Figures

Fig. 1:
Fig. 1:
Trend of haemoglobin levels and epoetin doses over time. RBC, red blood cells.
See this image and copyright information in PMC

References

    1. Gershon SK, Luksenburg H, Cote TR et al. . Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346: 1584–1586 - PubMed
    1. Macdougall IC, Casadevall N, Locatelli F et al. . PRIMS study group. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transplant 2015; 30: 451–460 - PMC - PubMed
    1. Haag-Weber M, Eckardt KU, Hörl WH et al. . Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 2012; 77: 8–17 - PubMed
    1. Casadevall N, Nataf J, Viron B et al. . Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469–475 - PubMed
    1. Hermeling S, Schellekens H, Crommelin DJ et al. . Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm Res 2003; 20: 1903–1907 - PubMed

LinkOut - more resources